UBS O'Connor’s RAPT Therapeutics RAPT Stock Holding History

UBS O'Connor’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,125	Closed	-$9.38K	–	592
2024 Q2	$9.38K	Hold	3,125	–	–	﹤0.01%	506
2024 Q1	$63.1K	Buy	+3,125	New	+$434K	﹤0.01%	434

Other funds holding RAPT

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

UBS O'Connor's RAPT Position: Q1 2025 in Review

UBS O'Connor sold out of RAPT Therapeutics (RAPT) in Q1 2025, closing a stake of 5,000 shares — an estimated $63.2K sold.

UBS O'Connor first reported a position in RAPT in Q1 2020 and held it in 9 quarters. The position peaked at $1.81M in Q2 2023. 92 funds tracked by Wall St. Rank hold RAPT as of Q1 2025.

UBS O'Connor reported no remaining RAPT Therapeutics position as of Q1 2025 after selling out during the quarter.
UBS O'Connor sold 5,000 RAPT Therapeutics shares in Q1 2025, an estimated $63.2K.
UBS O'Connor first reported a position in RAPT Therapeutics in Q1 2020 and held it in 9 quarters.
UBS O'Connor's RAPT Therapeutics position peaked at $1.81M in Q2 2023.
92 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q1 2025.

Based on UBS O'Connor's 13F filing for Q1 2025, filed 15 May 2025.